Multidrug-resistant tuberculosis management in resource-limited settings.
Multidrug-resistant tuberculosis management in resource-limited settings.
复制标题
DOI：
10.3201/eid1209.051618
复制
发表时间：
2006-09
影响因子：
11.8
通讯作者：
Raviglione MC
中科院分区：
文献类型：
--
作者：
Nathanson E;Lambregts-van Weezenbeek C;Rich ML;Gupta R;Bayona J;Blöndal K;Caminero JA;Cegielski JP;Danilovits M;Espinal MA;Hollo V;Jaramillo E;Leimane V;Mitnick CD;Mukherjee JS;Nunn P;Pasechnikov A;Tupasi T;Wells C;Raviglione MC
通过国家项目管理MDRTB可以产生类似于在较富裕环境中看到的结果。耐多药结核病(MDRTB)成功管理的证据主要来自高收入国家的转诊医院。我们评估了5个资源有限的国家--爱沙尼亚、拉脱维亚、秘鲁、菲律宾和俄罗斯联邦--MDRTB的管理情况。所有项目都得到了绿灯委员会的批准，以获得质量有保证的二线药物，并以较低的价格提供给MDRTB管理层。在评估的1,047名MDRTB患者中，119名(11%)是新患者，928名(89%)以前接受过治疗。超过50%的以前接受治疗的患者同时接受了一线和二线药物治疗，所有患者中有65%的患者感染同时对一线和二线药物耐药。所有患者的治疗成功率为70%，但新发患者的成功率(77%)高于之前接受治疗的患者(69%)。在资源有限的情况下，通过或与国家结核病规划合作提供的对MDRTB的治疗可以产生与较富裕环境中的结果类似的结果。
Managing MDRTB through national programs can yield results similar to those seen in wealthier settings. Evidence of successful management of multidrug-resistant tuberculosis (MDRTB) is mainly generated from referral hospitals in high-income countries. We evaluate the management of MDRTB in 5 resource-limited countries: Estonia, Latvia, Peru, the Philippines, and the Russian Federation. All projects were approved by the Green Light Committee for access to quality-assured second-line drugs provided at reduced price for MDRTB management. Of 1,047 MDRTB patients evaluated, 119 (11%) were new, and 928 (89%) had received treatment previously. More than 50% of previously treated patients had received both first- and second-line drugs, and 65% of all patients had infections that were resistant to both first- and second-line drugs. Treatment was successful in 70% of all patients, but success rate was higher among new (77%) than among previously treated patients (69%). In resource-limited settings, treatment of MDRTB provided through, or in collaboration with, national TB programs can yield results similar to those from wealthier settings.
登录
查看更多内容
影响因子：
3.3
作者：
Gupta, R;Cegielski, JP;Varaine, F
通讯作者：
Varaine, F
影响因子：
168.9
作者：
Suárez, PG;Floyd, K;Espinal, MA
通讯作者：
Espinal, MA
影响因子：
6.4
作者：
Zignol, Matteo;Hosseini, Mehran S.;Dye, Christopher
通讯作者：
Dye, Christopher
影响因子：
168.9
作者：
Coninx, R;Mathieu, C;Meddings, DR
通讯作者：
Meddings, DR
影响因子：
168.9
作者：
Gupta, R;Irwin, A;Kim, JY
通讯作者：
Kim, JY